Anne-Marie Martin is on the Board of Directors of Cullinan Oncology and currently Senior Vice President, Global Head of the Experimental Medicine Unit at GlaxoSmithKline. She is also a member of the Blood Profiling Atlas Consortium (Blood PAC), the Personalized Medicine Coalition and an executive committee member of the Partnership for Accelerating Cancer Therapies (FNIH-PACT).
Anne-Marie comes with a background of more than 20 years of medical experience in experimental medicine and research; and is an internationally trained scientist, thought leader and senior pharmaceutical executive. She has a successful track record in drug development, companion diagnostic development, and translational medicine across numerous therapeutic areas. Her experience in global regulatory science, medical affairs, business development, alliance management and global commercial insights convey her passion for people development, organizational culture, inclusion, and diversity.
Previously, Anne-Marie was Senior Vice President, Global Head of Precision Medicine at Novartis and Vice President, Head of Biomarker Research and Diagnostics at Adaptimmune. In addition to these roles, Anne-Marie’s career also includes a number of university appointments inclusive of teaching and research positions.
She received her undergraduate degree in biomedical sciences from Sheffield Hallam University, Sheffield, UK and a Ph.D. in Immunogenetics from MCP-Hahnemann University in Philadelphia.